Skip to main content
. 2021 Apr 21;11:8600. doi: 10.1038/s41598-021-87907-3

Table 2.

Characteristics of propensity score matched patients according to pre-existing depression.

Baseline characteristics Angina (n = 8,524) AMI (n = 4,692)
Overall (n = 8,524) Non-depression (n = 4,262) Depression (n = 4,262) p value Overall (n = 4,692) Non-depression (n = 2,346) Depression (n = 2,346) p value
Age, years 70.0 ± 10.1 70.1 ± 10.2 69.8 ± 9.9 0.710 70.9 ± 11.3 71.1 ± 11.3 70.6 ± 11.3 0.898
Men 4,327 (50.8%) 2,137 (50.1%) 2,190 (51.4%) 0.999 2,548 (54.3%) 1,267 (54.0%) 1,281 (54.6%) 0.394
Cormobidities
Diabetes 4,370 (51.3%) 2,208 (51.8%) 2,162 (50.7%) 0.548 2,022 (43.1%) 1,014 (43.2%) 1,008 (43.0%) 0.506
Hyperlipidemia 5,589 (65.6%) 2,786 (65.4%) 2,803 (65.8%) 0.464 2,260 (48.2%) 1,143 (48.7%) 1,117 (47.6%) 0.999
Hypertension 7,091 (83.2%) 3,576 (83.9%) 3,515 (82.5%) 0.948 3,466 (73.9%) 1,746 (74.4%) 1,720 (73.3%) 0.841
Congestive heart failure 1,175 (13.8%) 595 (14.0%) 580 (13.6%) 0.700 348 (7.4%) 169 (7.2%) 179 (7.6%) 0.613
Arrhythmia 1,135 (13.3%) 565 (13.3%) 570 (13.4%) 0.744 284 (6.1%) 136 (5.8%) 148 (6.3%) 0.852
Valvular disease 69 (0.8%) 38 (0.9%) 31 (0.7%) 0.810 12 (0.3%) 6 (0.3%) 6 (0.3%) 0.386
Peripheral vascular disease 1,807 (21.2%) 901 (21.1%) 906 (21.3%) 0.700 846 (18.0%) 431 (18.4%) 415 (17.7%) 0.394
Cerebrovascular disease 2,587 (30.3%) 1,263 (29.6%) 1,324 (31.1%) 0.778 1,048 (22.3%) 497 (21.2%) 551 (23.5%) 0.900
Chronic pulmonary disease 2,143 (25.1%) 1,074 (25.2%) 1,069 (25.1%) 0.999 930 (19.8%) 461 (19.7%) 469 (20.0%) 0.680
Moderate to severe liver disease 7 (0.1%) 2 (0.05%) 5 (0.1%) 0.999 5 (0.1%) 3 (0.1%) 2 (0.1%) 0.999
Renal disease 812 (9.5%) 415 (9.7%) 397 (9.3%) 0.910 330 (7.0%) 156 (6.6%) 174 (7.4%) 0.767
Cancer 246 (2.9%) 117 (2.7%) 129 (3.0%) 0.172 145 (3.1%) 68 (2.9%) 77 (3.3%) 0.733
Rheumatologic disease 30 (0.4%) 15 (0.4%) 15 (0.4%) 0.855 10 (0.2%) 4 (0.2%) 6 (0.3%) 0.343
Charlson comorbidity index 2.36 ± 1.67 2.33 ± 1.68 2.38 ± 1.66 0.668 1.90 ± 1.59 1.85 ± 1.61 1.96 ± 1.58 0.730
Types of treatment
Drug-eluting stent 7,905 (92.7%) 3,950 (92.7%) 3,955 (92.8%) 0.800 4,338 (92.5%) 2,165 (92.3%) 2,173 (92.6%) 0.955
Bioresorbable vascular scaffold 11 (0.1%) 3 (0.1%) 8 (0.2%) 0.546 14 (0.3%) 7 (0.3%) 7 (0.3%) 0.999
Bare-metal stent 46 (0.5%) 22 (0.5%) 24 (0.6%) 0.883 48 (1.0%) 24 (1.0%) 24 (1.0%) 0.665
Number of stent per person 1.42 ± 0.70 1.42 ± 0.69 1.42 ± 0.71 0.096 1.43 ± 0.68 1.44 ± 0.69 1.43 ± 0.67 0.465
Medication during hospitalization
Anti-platelet 8,433 (98.9%) 4,218 (99.0%) 4,215 (98.9%) 0.289 4,674 (99.6%) 2,336 (99.6%) 2,338 (99.7%) 0.239
Statin 7,260 (85.2%) 3,634 (85.3%) 3,626 (85.1%) 0.561 4,294 (91.5%) 2,150 (91.6%) 2,144 (91.4%) 0.874
B-blocker 5,016 (58.8%) 2,515 (59.0%) 2,501 (58.7%) 0.774 3,633 (77.4%) 1,829 (78.0%) 1,804 (76.9%) 0.728
ACEI/ARB 4,917 (57.7%) 2,447 (57.4%) 2,470 (58.0%) 0.999 3,283 (70.0%) 1,643 (70.0%) 1,640 (69.9%) 0.704

Data are mean ± standard deviation (SD) or number (%).

ACEI angiotensin-converting enzyme inhibitor, AMI acute myocardial infarction, ARB angiotensin receptor blocker.